Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
Checked against the public recordLast updated Jun 3, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Revolution Medicines, Inc.
- Interventions being studied
- Drug: RMC-9805; Drug: RMC-6236
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation * Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage * ECOG performance status 0 or 1 * Adequate organ function Exclusion Criteria: * Primary central nervous system (CNS) tumors * Known or suspected leptomeningeal or active brain metastases or spinal cord compression * Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication * Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors) Other inclusion/exclusion criteria may apply.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California, Davis Comprehensive Cancer CenterSacramento, California
- Smilow Cancer Hospital (Yale University)New Haven, Connecticut
- Florida Cancer SpecialistsSarasota, Florida
- Lee Moffitt Cancer CenterTampa, Florida
- Johns Hopkins UniversityBaltimore, Maryland
- Massachusetts General HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
- NYU LangoneNew York, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Duke Cancer CenterDurham, North Carolina
- Carolina BioOncology InstituteHuntersville, North Carolina
- The Christ HospitalCincinnati, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 3, 2026. Always confirm current availability with the study team.